VERTEX PHARMACEUTICALS INC (VRTX) Stock News
NASDAQ:VRTX - Nasdaq - US92532F1003 - Common Stock - Currency: USD
VRTX Latest News, Press Relases and Analysis
10 Brilliant Growth Stocks to Buy Now and Hold for the Long Term
With just a little bit of a deeper look, these businesses are positioned for long-term growth.
$100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth This Much Today
Vertex to Announce Second Quarter 2025 Financial Results on August 4th
Do You Believe in the Upside Potential of Vertex Pharmaceuticals (VRTX)?
PGIM Jennison Health Sciences Fund released its first quarter 2025 investor letter. A copy of the letter can be downloaded here. The S&P 1500 Health Care Index returned 5.5% in the first quarter, outperforming the S&P 500’s -4.3% return. Biotechnology and healthcare providers and services surpassed the Index in performance during this quarter. Pharmaceuticals, healthcare […]
Intellia Gains 29.8% in a Month: How Should You Play the Stock?
NTLA stock surges 29.8% in a month, driven by gene therapy pipeline progress and growing investor attention.
The Best Stocks to Invest $1,000 In Right Now
Alibaba offers a cheap way to invest in artificial intelligence (AI), cloud computing, digital media, and e-commerce. UnitedHealth Group is a bargain after its steep sell-off. Vertex Pharmaceuticals has two new drugs on the market and a promising pipeline.
H.C. Wainwright Reaffirms Vertex Buy Rating After ADA Conference Results
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ranks among the best fundamental stocks to buy according to hedge funds. With a price target of $550, H.C. Wainwright reaffirmed its Buy rating on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on June 23. The update comes after the American Diabetes Association (ADA) conference featured updated data from Vertex’s zimislecel program. According to […]
Vertex and Ono Pharmaceutical Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea
Mentions: OTC
Vertex Presents Positive Data for Zimislecel in Type 1 Diabetes at the American Diabetes Association 85th Scientific Sessions
Here's Why Vertex Pharmaceuticals (VRTX) Fell More Than Broader Market
In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $440.87, denoting a -1.68% move from the preceding trading day.
Vertex (VRTX) Stock PT Lowered to $420 on slower Alyftrek Uptake
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the 10 biotech stocks screaming a buy. On June 17, RBC Capital reiterated a Sector Perform rating on the stock but cut the price target to $420 from $423. The adjustment is in response to the company confirming gradual patient conversion from Trikafta to the company’s next-generation cystic […]
2 Growth Stocks to Buy and Hold for 10 Years
A decade after its IPO, Shopify still has the qualities that allowed it to deliver significantly above average returns. Despite recent issues, Vertex Pharmaceuticals' innovative lineup and pipeline should lead to strong performances.
Mentions: SHOP
United States Steel Corporation (X) Should Not Have Been Bought By Nippon, Says Jim Cramer
We recently published a list of Jim Cramer Finds Elon Musk’s Grok AI Creepy & Discusses These 12 Stocks. In this article, we are going to take a look at where United States Steel Corporation (NYSE:X) stands against other stocks that Jim Cramer discussed. United States Steel Corporation (NYSE:X) is an American steel company headquartered […]
JPMorgan Calls the Selloff Excessive, Trims Regeneron Pharmaceuticals, Inc. (REGN) Price Target
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 13 Biotech Stocks with Huge Upside Potential. JPMorgan has maintained its Overweight rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) after reducing its price objective from $950 to $800. Following poor IL-33 data in late May, the company believes that the recent selloff in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) shares […]
Jazz Pharmaceuticals Releases Unexpected Phase 4 Results Highlighting Xywav®
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is one of the 13 Biotech Stocks with Huge Upside Potential. Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is one of the stocks with the biggest upside. It presented late-breaking Phase 4 data on Xywav® at SLEEP 2025, which included findings from the XYLO and DUET trials. In the XYLO study (n=43), moving from […]
Vertex Presents New Data on the Benefits of ALYFTREK
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the 13 Biotech Stocks with Huge Upside Potential. The company shared new data at the 48th European Cystic Fibrosis Conference, revealing that ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) is linked with improved clinical outcomes and quality of life in cystic fibrosis (CF) patients. A pooled research found that sweat chloride (SwCl) levels […]
The European Commission Approves Alnylam’s AMVUTTRA
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the 13 Biotech Stocks with Huge Upside Potential. It declared on June 9, 2025, that AMVUTTRA® (vutrisiran) has been approved by the European Commission to treat wild-type or hereditary ATTR amyloidosis with cardiomyopathy (ATTR-CM). As a result, AMVUTTRA is the first and only RNAi treatment approved in the […]